Monash IVF Group Ltd represents values of excellence, innovation, and patient-centered care. With a corporate philosophy focused on fulfilling the dreams of parenthood, Monash IVF Group Ltd is dedicated to providing cutting-edge fertility treatments and personalized support to couples and individuals. By leveraging its extensive experience and technological advancements, the company strives to deliver superior reproductive medicine services. Monash IVF Group Ltd maintains its commitment to the highest ethical standards, transparency, and fostering a compassionate and inclusive environment for its patients.

Monash IVF Group Ltd primarily operates in Australia and Malaysia. Australia is its main market, where it has multiple clinics located across the country. Additionally, the company has a significant presence in Malaysia, offering fertility services through its strategic partnership with Sunfert International. Monash IVF Group Ltd's focus on these countries and regions allows it to provide comprehensive reproductive and fertility services to patients, including in vitro fertilization (IVF), genetic testing, and other related treatments.

Monash IVF Group Ltd has achieved several significant milestones. The company has a strong track record of delivering high success rates in assisted reproductive technologies such as in vitro fertilization (IVF) and has assisted in the birth of over 30,000 babies. Monash IVF Group Ltd has also pioneered innovative fertility treatments and technologies, including the development of genetic testing for embryos and advancements in egg freezing techniques. The company's commitment to research and clinical excellence has made them a leading player in the fertility industry, earning them a reputation for delivering exceptional patient outcomes and maintaining a position at the forefront of reproductive medicine.

Monash IVF Group Ltd, founded in 2000, is a leading Australian fertility services provider. Specializing in assisted reproductive technology and treating infertility, the company has a rich history of pioneering advancements. Monash IVF Group Ltd operates a network of fertility clinics, offering comprehensive services such as in vitro fertilization, fertility testing, and sperm and egg donation. With a team of highly skilled specialists, the company is committed to delivering exceptional patient care and achieving strong success rates in fertility outcomes. Monash IVF Group Ltd has grown to become a trusted name in the fertility industry, consistently providing hope and support to individuals and couples seeking to start or expand their families.

Some of the main competitors of Monash IVF Group Ltd in the market include Virtus Health Limited, Healthscope Limited, and Genea Limited. These companies also operate in the fertility services sector and compete with Monash IVF Group Ltd in providing reproductive and infertility treatments.

Monash IVF Group Ltd is primarily active in the healthcare and biotechnology industries.

Monash IVF Group Ltd operates as a leading fertility provider in Australia. The company's business model focuses on offering a comprehensive range of assisted reproductive services. Monash IVF Group specializes in fertility treatments, including in vitro fertilization (IVF), sperm and egg donation, genetic testing, and surrogacy. With a dedicated team of specialists and advanced laboratory facilities, Monash IVF Group aims to help individuals and couples achieve their dream of having a family. By combining cutting-edge technology, personalized care, and research advancements, the company strives to deliver the highest quality fertility care to its patients.

De Monash IVF Group K/W is 15,69.

De Monash IVF Group KUV is 1,82.

De AlleAktien Kwaliteitsscore voor Monash IVF Group is 5/10.

De verwachte Monash IVF Group omzet is 255,82 mln. AUD.

De verwachte Monash IVF Group winst is 29,63 mln. AUD.

Monash IVF Group Ltd is an Australian-based company that specializes in providing assisted reproductive technology (ART) and the investigation and treatment of infertility. The company currently operates multiple fertility clinics and laboratories in Australia and New Zealand. The company offers a wide range of reproductive and fertility services that focus on meeting the specific needs and requirements of each customer. This includes in-vitro fertilization (IVF), intrauterine insemination (IUI), sperm and egg donation, as well as preimplantation diagnosis (PID) and genetic testing. Monash IVF Group has also specialized in researching and developing new technological approaches for assisted reproduction. This includes an extensive research program that focuses on investigating factors that influence fertility, such as lifestyle factors, environmental influences, and genetic predispositions. Another important aspect of the company is the education of doctors, nurses, and other professionals in assisted reproduction. Monash IVF Group offers a variety of courses, training, and workshops to constantly improve and develop knowledge and skills in the field of assisted reproductive technologies. In addition to its clinical services and research program, Monash IVF Group also operates its own diagnostic laboratory that offers a wide range of tests for diagnosing infertility. This includes hormone analysis, semen analysis, and genetic testing. The company is also able to extend its services to international customers. Monash IVF Group has a strong presence in Asia and currently operates clinics in Malaysia and Singapore. Overall, Monash IVF Group has a comprehensive business model that focuses on providing high-quality reproductive and fertility services, conducting innovative research programs, educating professionals, and expanding international markets. The company is well-positioned to grow its customer base and expand its range of services and products to meet the changing demands in the field of assisted reproductive technology.

Monash IVF Group keert een dividend van 0,06 AUD uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Monash IVF Group of het bedrijf keert geen dividend uit.

De ISIN van Monash IVF Group is AU000000MVF3.

Het WKN van Monash IVF Group is A116LZ.

De ticker van Monash IVF Group is MVF.AX.

Binnen de laatste 12 maanden betaalde Monash IVF Group een dividend van 0,06 AUD . Dit komt overeen met een dividendrendement van ongeveer 5,30 %. Voor de komende 12 maanden zal Monash IVF Group naar verwachting een dividend van 0,06 AUD betalen.

De dividendrendement van Monash IVF Group is momenteel 5,30 %.

Monash IVF Group betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden april, oktober, april, oktober.

Monash IVF Group betaalde de afgelopen 13 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0,06 AUD verwacht. Dit komt overeen met een dividendrendement van 5,26 %.

Monash IVF Group wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Monash IVF Group van 11-10-2024 ter hoogte van 0,036 AUD te ontvangen, moest je het aandeel voor de ex-datum op 5-9-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 11-10-2024.

In het jaar 2023 heeft Monash IVF Group 0,063 AUD aan dividenden uitgekeerd.

De dividenden van Monash IVF Group worden in AUD uitgekeerd.